Association of serum uric acid levels with COVID-19 severity

Hu, Fang; Guo, Yifan; Lin, Jianghong; Zeng, Yanjun; Wang, Juan; Li, Man; Li, Cong

doi:10.1186/s12902-021-00745-2

Cited by 18 publications

(26 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is in line with previous studies. In a recent study by Chang et al, 34 low UA levels were linked to an increased risk of trigeminal neuralgia, which is consistent with our findings in acute and chronic herpetic pain. Because patients with HZ are at a high risk of developing PHN, early and effective interventions can help reduce the occurrence of the disease.…”

Section: Discussionsupporting

confidence: 93%

Antioxidant and inflammatory biomarkers in herpes zoster

Oskay

Keskin

Özen

2022

Journal of Medical Virology

View full text Add to dashboard Cite

The risk of herpes zoster (HZ) increases as cell-mediated immunity declines with age.Even though oxidative stress plays a crucial role in the development of HZ, there are few serum biomarkers of the disease's antioxidant activity. The purpose of this study is to investigate the blood levels of major antioxidants in HZ patients. To the best of our knowledge, this is the first study on this issue in the literature. The serum levels of antioxidants including uric acid (UA), total bilirubin (TBİL), albumin (ALB), vitamin D levels, and inflammatory markers such as homocysteine (Hcy) and C-reactive protein (CRP) was retrospectively analyzed in 53 patients with HZ and 53 age-and sex-matched healthy controls (HCs). The relationships between these markers and postherpetic neuralgia (PHN) and the clinical severity of HZ were also evaluated.Serum levels of UA, TBIL, and ALB in patients with HZ were significantly lower than those in the HCs (p < 0.001), while no statistical differences were found in vitamin D levels between the groups. Hcy and CRP levels were significantly increased in HZ patients compared to HCs. Significant differences were observed in the serum levels of UA, Hcy, CRP, and vitamin D in the PHN group versus the non-PHN group (p < 0.001). The presence of inflammatory markers was found to be positively related to disease activity. Furthermore, when compared to the mild or moderate clinical types of HZ, these biomarkers were statistically significant in the severe clinical type.These results suggest that uncontrolled varicella-zoster virus reactivation, acute nerve damage, and PHN may all be associated with low antioxidant levels. These biomarkers may be a protective factor for HZ, but more research is needed to clarify the underlying mechanism.

show abstract

Section: Discussionsupporting

confidence: 93%

Antioxidant and inflammatory biomarkers in herpes zoster

Oskay

Keskin

Özen

2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…These suggest that low uric acid levels may indicate a higher in ammatory status and death risk in patients with COVID-19. Previous studies have shown that serum uric acid levels are lower than normal in patients with COVID-19 [20][21][22][23]. In our analysis, blood uric acid level was found to be an independent prognostic factor on survival in patients lung cancer with COVID-19 patients (p = 0.008).…”

Section: Discussionsupporting

confidence: 54%

Uric Acid and Hemoglobin as Prognostic Factors in Lung Cancer with COVID-19

OzkanOzturk¹,

Kocaman²,

İnal³

2022

Preprint

View full text Add to dashboard Cite

Background Cancer patients have an increased risk of COVID-19 compared to the healthy population. Due to increased proinflammatory cytokine excess, unopposed excessive immune response, that is, systemic inflammatory response; is the most important reason that increases the risk of mortality. In this study, we aimed to examine the parameters and inflammatory indices affecting mortality in lung cancer patients with COVID-19. Methods This single-center retrospective study included 66 patients diagnosed with lung cancer and treated for COVID-19 between April 2020 and July 2021. Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), prognostic index (PI), modified Glasgow prognostic score (mGPS), and COVID inflammatory score (OIS) were calculated for all patients. Twenty-seven potential prognostic variables were chosen for univariate and multivariate analyses. Results A total of 28 variables were analyzed univariable. Seven variables were identified to have prognostic significance: receiving chemotherapy in the last 28 days, hospitalization in the intensive care unit, mechanical ventilation requirement, COVID 19 corticosteroid treatment doses, hemoglobin, platelet count, uric acid. Multivariate analysis by Cox proportional hazard model, including seven prognostic significance factors evident in univariate analysis. In the multivariate logistic regression analysis; hemoglobin, uric acid were independent risk factors for severe COVID-19 in lung cancer. Conclusion Serum hemoglobin and uric acid level were identified as important prognostic factors in lung cancer patients with COVID-19. These findings may facilitate the prediction of survival in lung cancer patients with COVID-19. In the literature, there is no previous study on the effect of uric acid on prognosis in patients with COVID-19 and lung cancer. Prospective studies with larger patient populations are needed to confirm this study.

show abstract

“…Fifth, the potential effect of severity (disease activity) in gout could not be assessed (eg, the presence or absence of tophus or flare frequency). Sixth, in the context of reports of a U-shaped relationship between serum urate levels and COVID-19 outcomes, 23 , 24 , 25 we were unable to investigate any effect of serum urate levels on COVID-19 related death, as these data are unavailable in the UK Biobank. Seventh, the medicine prescribing data were single script from general practitioners only; there was no way of ascertaining adherence or whether participants were taking the medication during the COVID-19 pandemic, although we attempted to account for this by only using prescription information from 2019 and 2020.…”

Section: Discussionmentioning

confidence: 97%

Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study

Topless

Gaffo

Stamp

et al. 2022

The Lancet Rheumatology

View full text Add to dashboard Cite

Background There is a paucity of data on outcomes for people with gout and COVID-19. We aimed to assess whether gout is a risk factor for diagnosis of COVID-19 and COVID-19-related death, and to test for sex- and drug-specific differences in risk. Methods We used data from the UK Biobank, which included 15 871 people with gout. We used multivariable-adjusted logistic regression in the following analyses using a case-control study design: to test for an association between gout and COVID-19 diagnosis in the entire UK Biobank cohort (n=459 837); to test for an association between gout and COVID-19-related death in people who were known to have died or survived with COVID-19 (n=15 772); to test for an association between gout and COVID-19-related death in the entire UK Biobank cohort (n=459 837); and to assess risk of COVID-19-related death in a subset of patients from the UK Biobank cohort with prescription data, stratified by prescription of urate-lowering therapy and colchicine (n=341 398). Models 1 and 2 were adjusted for age group, sex, ethnicity, Townsend deprivation index, BMI, and smoking status. Model 2 was also adjusted for diagnosis of 16 other diseases that are established comorbidities of gout or established risk factors for COVID-19-related death. Findings Gout was associated with diagnosis of COVID-19 (odds ratio [OR] 1·20, 95% CI 1·11–1·29) but not with risk of COVID-19-related death in the cohort of patients diagnosed with COVID-19 (1·20, 0·96–1·51). In the entire cohort, gout was associated with COVID-19-related death (1·29, 1·06–1·56); women with gout had an increased risk of COVID-19-related death (1·98, 1·34–2·94), whereas men with gout did not (1·16, 0·93–1·45). We found no significant differences in the risk of COVID-19-related death according to prescription of urate-lowering therapy or colchicine. When patients with gout were stratified by vaccination status, the risk of diagnosis with COVID-19 was significant in the non-vaccinated group (1·21, 1·11–1·30) but not the vaccinated group (1·09, 0·65–1·85). Interpretation Gout is a risk factor for COVID-19-related death in the UK Biobank cohort, with an increased risk in women with gout, which was driven by risk factors independent of the metabolic comorbidities of gout. Funding Health Research Council of New Zealand.

show abstract

Association of serum uric acid levels with COVID-19 severity

Cited by 18 publications

References 32 publications

Antioxidant and inflammatory biomarkers in herpes zoster

Antioxidant and inflammatory biomarkers in herpes zoster

Uric Acid and Hemoglobin as Prognostic Factors in Lung Cancer with COVID-19

Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study

Contact Info

Product

Resources

About